What It Actually Costs When Hope Is the Product

Cancer is not an abstraction. For anyone who has watched a person they love go through chemotherapy, or sit through scans waiting for results, or spend their savings on treatments that might buy a few more months, the word carries a specific gravitational weight. It means fear. It means the particular helplessness of watching medicine do its best and sometimes still fail. It means that when someone shows up with a device that could filter tumor cells out of a patient’s blood, the way a dialysis machine filters waste, the people who hear that pitch do not just see a financial opportunity. They see something they need to be true.

That is the thing Sumit Rai understood. He is not accused of targeting strangers with cold calls. The SEC’s complaint describes an investor network built over years, more than 180 unique individuals who were approached through personal connections, venture capital circles, and pitch materials that described a medically plausible technology in language designed to sound like legitimate science. Many of them were brought in early, invested, and then asked to roll their notes into a new entity. Then another new entity. Each time, the story evolved slightly. The CE Mark was coming. FDA approval was “anticipated” for 2023. Commercial sales would start in 2024. Onco was heading to NASDAQ.

None of it was happening. While the pitch decks were being updated with new timelines, Rai was withdrawing cash by the millions. He was paying a credit card bill stacked with restaurant charges and luxury clothing purchases for himself and a man the complaint identifies only as Person B, someone described as purportedly connected to celebrities and wealthy individuals. He was buying cars for a Manhattan social club. He was spending $85,000 at two strip clubs in Texas over the span of two days. The complaint is matter-of-fact about this. It is written in the language of securities law. But read between the lines and what you find is a person who looked at money that had been given to him to fight cancer, and decided it was his.

The investors who eventually ended up holding Onco promissory notes now hold paper with a face value of at least $210 million. The first payment was due December 31, 2024. It was not made. Rai had written a clause into the notes allowing him to push back the payment date whenever he wanted. He pushed it back. As of the filing of this complaint in January 2026, no payment has ever been made to any noteholder.

The complaint does not describe a single investor’s name or story, because that is not what SEC complaints are for. But the math tells you enough. One hundred investors came in through SVN Med. Sixty more through NVS Med. Seventy more directly into Onco. These were people who believed, because they were told to believe, that their capital was going toward something that could change how cancer is treated. Some of them were likely personal contacts of Rai’s, people who trusted him because they knew him. Some of them were institutions doing due diligence and receiving falsified brokerage statements with key disclosures literally cut out of the document. All of them are now creditors of a shell holding a $210 million obligation that shows every sign of being unpayable.

Kim de Mora, who served as CEO of SVN Med for nearly three years, is not accused of being the architect of this fraud. But the complaint makes clear he was not a passive bystander. He signed the documents that pledged investor money as collateral for Rai’s personal loan. He approved large cash withdrawals when the bank called to verify them, without asking Rai a single question about what the money was for. When the company’s bookkeepers tried to find out why $10.6 million had just left the account, de Mora forwarded their email to Rai and asked him what to say. The answer Rai gave him was a lie, and de Mora told it. He also took $150,000 in undocumented, interest-free loans from the companies over three years and never repaid a dollar. The complaint calls his conduct “at least reckless.” That is the legal threshold. The human one is something else.

The investors in this case were not promised a sure thing. Private placements carry risk. But they were promised that their money would go toward what they were told it would go toward. That is the basic covenant of any investment: you say what you will do with the money, and then you do it. When 180 people hand over a collective $26.7 million to develop a cancer-fighting medical device, and that money instead flows to nightclubs, strip clubs, luxury vehicles, jewelry, and the personal debts of a socialite with celebrity connections, something beyond financial loss has occurred. Trust was manufactured, sold, and spent.

From First Pitch to Federal Complaint: The Full Chronology

The scheme ran for over six years, with each phase designed to funnel earlier investor money into new structures that reset the clock on repayment.

$10.6 Million in Investor Cash: Where It Actually Went

The SEC complaint traces every documented category of Rai’s misappropriation. The figures below come directly from the complaint’s factual allegations.

• $5.1 million was withdrawn in cash from the loan account and handed primarily to Person B for restaurants, nightclubs, and entertainment. Rai kept no documentation of how this cash was spent.
• $2.3 million was paid toward personal credit card bills for Rai and Person B, including $1.6 million at restaurants, $350,000 on clothing, jewelry, and accessories, $107,000 on home furnishings and exercise equipment, and $70,000 on alcohol.
• $1 million was used to pay off Person B’s personal debts that were not on a credit card. Person B is described in the complaint as someone with connections to celebrities and wealthy individuals.
• $1.5 million was used by Rai to purchase equity in SVN Med and Onco in his own name, increasing his personal ownership stake using money that belonged to other investors.
• $850,000 was spent on luxury vehicles for an “elite private social club in Manhattan” that Rai and Person B were co-founding. The club never opened.
• $680,000 was paid in interest charges on the personal loan, primarily drawn from the investor-funded brokerage account pledged as collateral.
• $85,000 was spent over two days at two strip clubs in Texas, charged to Rai’s personal credit card and ultimately paid using loan proceeds.
• $22,500 was loaned to co-defendant Kim de Mora in December 2022 from loan proceeds. This loan was undocumented at the time it was made.

The Documents Don’t Lie: Verbatim From the Complaint

Every quote below is pulled directly from the SEC complaint filed January 15, 2026. No paraphrasing. No editorializing. These are the specific facts the federal government put under oath.

What Investors Were Told vs. What Was Actually Happening

Rai’s pitch evolved across three companies and four years, but the core deception stayed constant. The following contrasts are drawn directly from the complaint’s factual allegations.

Who Gets Hurt When Cancer Fraud Goes Unchecked

Public Health

This fraud did not just steal money. It occupied the space where real cancer research could have existed, wasted years of potential development time, and eroded the credibility of early-stage medical investment.

• Patients who might benefit from an actual circulating tumor cell filtration device remain without it. Every year and every dollar that went toward maintaining the illusion of research was a year and a dollar not going toward the real thing from a legitimate company.
• Rai’s pitch materials described a device capable of filtering a patient’s “entire blood volume” to inhibit cancer metastasis. This language was presented to investors in ways designed to sound like verified science. When patients or their families hear about such technologies through secondary channels, false hope has a measurable psychological and practical cost.
• The complaint documents that Cancer Check is actively selling a blood test “for diagnosing cancer from circulating tumor cells” to patients right now, using Onco’s products. There is no documented FDA clearance for commercial use referenced in the complaint. The regulatory status of this product being sold to cancer patients is, based on the complaint’s record, unresolved.
• The capital vacuum created by this fraud specifically affects the early-stage medical device funding ecosystem. Legitimate cancer diagnostic startups competing for the same pool of individual and institutional investors face a harder road when bad actors poison the well.

Economic Inequality

The structure of this fraud targeted the machinery of private capital markets and exploited the trust of individual investors who had fewer protections than institutional ones.

• More than 180 investors collectively put in $26.7 million. Many of them were individuals, not institutions. Individual investors in private placements have no secondary market, no liquidity, and no regulatory backstop equivalent to FDIC insurance. Their only protection was the representations made to them about how their money would be used.
• Institutional investors who did conduct due diligence were actively deceived with falsified documents. The $3 million institutional investor who requested a brokerage statement received a doctored copy with loan collateral disclosures physically removed. Due diligence is supposed to be the safeguard that catches this. It was defeated by forgery.
• The note-rolling structure Rai built across SVN Med, NVS Med, and Onco is a textbook technique for extending the life of an unsustainable scheme. Each roll reset the payment clock, inflated nominal face values to appear generous, and introduced new terms. Investors who had already committed could not easily exit without accepting a loss, creating a coercive dynamic.
• Rai used $1.5 million of investor money to buy equity in the same companies in his own name. This directly diluted the economic interest of the investors whose money he was taking. He stole from them and used the proceeds to buy more of what he was stealing from them.
• De Mora extracted $150,000 in undocumented, interest-free loans from investor-funded companies over three years. These were not disclosed to investors, had no repayment terms, and have not been repaid. For reference: the complaint notes that each of these loans “represented a substantial portion of de Mora’s annual salary” at the time they were made.
• Outstanding notes now carry a face value of at least $210 million. If Rai’s unilateral payment extensions are allowed to stand, 180+ investors face years of further waiting. The actual principal they invested ($26.7 million) has already been largely spent. The inflated face values of the rolled notes are mathematical claims against a company whose only asset pipeline was redirected to a separately owned entity that owes it nothing.

What $85,000 Over Two Days Actually Means

The Process That Should Have Stopped This. And Didn’t.

Multiple procedural checkpoints existed to catch exactly this type of fraud. Each one was either bypassed, falsified, or actively corrupted by an insider.

The People Responsible, the Bodies That Can Act, and What You Can Do

The SEC filed this complaint on January 15, 2026. The defendants are named. The watchdogs are in motion. Here is who is accountable, who has jurisdiction, and how regular people can push this forward.

Named Defendants and Their Roles

• Sumit Rai, CEO and Founder of NVS Med and Onco Filtration Inc., and CEO/Founder/Chairman of Cancer Check Labs LLC, Dallas, Texas. Rai faces permanent injunction, officer and director bars, civil penalties, disgorgement, and a prohibition on participating in securities issuance or sale.
• Kim de Mora, former CEO of SVN Med and former VP of Technology at Onco Filtration, North Billerica, Massachusetts. De Mora faces officer and director bars, civil penalties, and disgorgement for aiding and abetting violations.
• SVN Med LLC, NVS Med Inc., and Onco Filtration Inc. face permanent injunctions and disgorgement as corporate defendants.
• Cancer Check Labs LLC, formed by Rai on September 26, 2023, is named as a Relief Defendant. The SEC seeks disgorgement of the $915,000+ in revenue it collected from Onco’s products without paying Onco.

Regulatory Watchlist

• SEC Boston Regional Office (primary): Lead investigators are Kathleen Burdette Shields and Brandon Sisson. Contact: ShieldsKa@sec.gov; SissonB@sec.gov; 617-573-8904. This office filed the complaint and is the active enforcement body.
• U.S. District Court, District of Massachusetts: Civil Action No. 1:26-cv-10159 is the active case number. Court filings are public record via PACER (pacer.gov).
• FDA Office of Criminal Investigations: If Cancer Check’s blood test product is being sold to patients without appropriate FDA clearance, this is the body with jurisdiction over that potential violation. The complaint documents active patient sales.
• Texas State Securities Board: Rai is based in Dallas. The TSSB has independent authority to investigate and pursue securities fraud by Texas residents.
• Delaware Secretary of State: SVN Med, NVS Med, Onco, and Cancer Check are all Delaware corporations. Delaware courts have jurisdiction over corporate governance questions arising from the structure of these entities.

What You Can Do Right Now

• If you are a current investor in SVN Med, NVS Med, Onco Filtration, or Cancer Check Labs, you are a potential victim in this complaint. Contact the SEC Boston Regional Office directly. You can also consult a securities fraud attorney. Many handle investor fraud cases on contingency.
• Submit a tip to the SEC Whistleblower Program at sec.gov/whistleblower if you have information about this case or related conduct. Tips are anonymous and may be eligible for financial awards if they lead to enforcement action exceeding $1 million.
• Report to your state attorney general. If you are an investor based in Massachusetts, Texas, or any other state, your AG has consumer protection jurisdiction and may be pursuing parallel investigations.
• Support investor protection advocacy organizations that push for stricter disclosure requirements on private placements and convertible note structures. NASAA (North American Securities Administrators Association) and the Public Investors Advocate Bar Association (PIABA) both work on exactly this type of systemic vulnerability.
• Share this investigation with anyone who has been pitched a private cancer-related investment in the past five years, particularly one involving the terms “cancer dialysis,” “circulating tumor cells,” “CE Mark approval,” or “FDA Breakthrough Application.” The investor network Rai built was person-to-person. Awareness travels the same way.
• At the community level: local investor protection clinics, often run through law school legal aid programs, can help individuals understand their rights and options without the cost of private counsel. Check with your nearest accredited law school’s clinic program.